臓器移植の拒絶反応治療薬の世界市場

臓器移植の拒絶反応治療薬の世界市場は2030年までに60億米ドルに達する見込み

2024年に51億米ドルと推定される臓器移植の拒絶反応治療薬の世界市場は、2024年から2030年にかけてCAGR 2.5%で成長し、2030年には60億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗体は、CAGR 1.7%を記録し、分析期間終了時には27億米ドルに達すると予想されます。代謝拮抗薬セグメントの成長率は、分析期間中CAGR 3.4%と推定されます。

米国市場は14億米ドルと推定、中国はCAGR 4.7%で成長予測

米国の臓器移植の拒絶反応治療薬市場は、2024年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と1.8％と予測されています。欧州では、ドイツがCAGR 1.4%で成長すると予測されています。

世界の臓器移植の拒絶反応治療薬市場- 主要動向と促進要因まとめ

なぜ免疫抑制療法が臓器移植の成功と長寿の中心なのか？

臓器移植の拒絶反応治療薬-免疫抑制療法としても知られる-は、宿主の免疫系が移植臓器を攻撃し破壊するのを防ぐために不可欠です。これらの薬剤は移植後の治療の基幹をなすもので、移植片の生存を保証し、合併症を最小限に抑え、患者のQOLを向上させるために極めて重要です。これらの薬剤は、移植直後（導入期）、維持期、急性拒絶反応時に使用され、免疫反応を調節します。

腎臓、肝臓、心臓、肺、膵臓などの固形臓器移植の世界の増加は、信頼性が高く安全な免疫抑制レジメンへの需要を促進しています。外科手術の進歩や移植後のモニタリングにより生存率が向上する中、免疫反応の長期管理が重要な治療上の優先課題となっています。移植片の拒絶反応に関与する免疫シグナル伝達経路は複雑であるため、カルシニューリン阻害剤（タクロリムスなど）、mTOR阻害剤（シロリムスなど）、コルチコステロイド、ミコフェノール酸モフェチルのような抗増殖剤を組み合わせた多剤併用療法が必要となります。これらの薬物療法における絶え間ない技術革新により、より優れた耐性、より少ない感染症、慢性毒性の軽減が可能になりつつあります。

新しい治療標的と製剤は、拒絶反応の管理と患者の転帰をどのように改善しているのでしょうか？

最近の免疫学と分子薬理学の動向により、より選択的な作用機序を持ち、副作用プロファイルが改善された新規免疫抑制剤の開発が進んでいます。共刺激遮断薬（ベラタセプトなど）やモノクローナル抗体（バシリキシマブなど）は、従来のカルシニューリン阻害薬に伴う腎毒性を伴わずに、T細胞活性化経路を標的として阻害します。これらの薬剤は腎移植患者や合併症を有する患者において特に有用です。

徐放錠、腸溶性コーティングカプセル、ナノキャリアベースのドラッグデリバリーなどの製剤改良により、服薬アドヒアランスと薬物動態の安定性が向上しています。治療薬モニタリング（TDM）は、ポイント・オブ・ケア・アッセイやファーマコゲノミック・プロファイリングによってより正確になってきており、臨床医が投与量を個別化し、拒絶反応のリスクを低減することを可能にしています。また、寛容導入レジメンを開発する研究も進行中であり、これによって生涯にわたる免疫抑制が不要になる日が来るかもしれないです。これらの技術革新により、移植後の薬物療法は大きく変化し、移植片の生存率と患者のQOLの両方が改善されつつあります。

どのような患者集団と地域の医療システムが抗拒絶反応薬の需要を牽引しているか？

腎移植患者が免疫抑制療法使用者の最大セグメントを占めており、次いで肝移植患者と心臓移植患者です。小児および老人移植患者では、代謝や免疫系の挙動が異なるため、特殊な投与・モニタリング戦略が必要となります。再移植を受ける患者やパネル反応抗体（PRA）が高値の患者は、拒絶反応や移植片の不全を防ぐために、より強力なレジメンや多剤併用レジメンを必要とすることが多いです。

米国は、移植件数の多さ、先進的なドナーマッチングシステム、公的および民間保険プランへの免疫抑制剤の組み入れにより、世界の採用率でリードしています。欧州は、協調的な移植ネットワークと集中的な移植後ケアにより、強力な地位を維持しています。アジア太平洋地域は、特にインド、中国、日本で急速な成長を遂げており、臓器移植プログラムの規模が拡大し、免疫抑制剤の価格も改善しています。ラテンアメリカや中東の新興市場では、公的医療資金や世界製薬会社との地域提携を通じて、アクセスが拡大しています。

臓器移植の拒絶反応治療薬市場の長期的成長と戦略的革新の原動力は？

臓器移植の拒絶反応治療薬市場の成長の原動力となっているのは、移植手術の成功率とアクセスの向上、移植後の生存期間の延長、世界の臓器提供率の上昇です。免疫抑制剤への長期的な依存は、移植適格患者数の増加と相まって、継続的な需要と市場の安定性を保証しています。さらに、精密投与、標的治療、バイオシミラー開発における技術革新は、費用対効果を改善しつつ、治療の選択肢を広げています。

製薬会社は、免疫寛容を誘導し、長期的な薬物依存を減らすために、次世代生物製剤、T調節細胞療法、遺伝子編集戦略を模索しています。移植センター、バイオテクノロジー企業、学術機関の間の戦略的協力関係は、臨床試験の加速化と実臨床でのデータ作成を促進しています。慢性拒絶反応を軽減し、長期的な移植片機能を改善する治療法の早期開発に対する規制当局の支援は、技術革新をさらに後押ししています。世界の移植エコシステムが個別化、持続可能、高結果のプロトコールに向けて進化するにつれて、拒絶反応治療薬市場は拡大と多様化を続けると思われます。

セグメント

薬剤クラス（抗体、代謝拮抗薬、ステロイド、その他薬剤クラス）、移植タイプ（腎移植、肝移植、心臓移植、肺移植、その他移植タイプ）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例（注目の32社）

• AbbVie Inc.
• Accord Healthcare Ltd.
• Astellas Pharma Inc.
• Biocon Limited
• Bristol-Myers Squibb Company
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Genzyme Corporation
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd.
• Hansa Biopharma AB
• Hikma Pharmaceuticals plc
• Mylan Laboratories Inc.
• Novartis AG
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Veloxis Pharmaceuticals A/S
• Viatris Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Organ Transplant Rejection Medications Market to Reach US$6.0 Billion by 2030

The global market for Organ Transplant Rejection Medications estimated at US$5.1 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Antibodies, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Antimetabolites segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 4.7% CAGR

The Organ Transplant Rejection Medications market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 4.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Organ Transplant Rejection Medications Market - Key Trends & Drivers Summarized

Why Is Immunosuppressive Therapy Central to the Success and Longevity of Organ Transplantation?

Organ transplant rejection medications-also known as immunosuppressive therapies-are essential for preventing the host immune system from attacking and destroying the transplanted organ. These medications form the backbone of post-transplant care and are critical to ensuring graft survival, minimizing complications, and improving patient quality of life. They are used immediately after transplantation (induction phase), throughout the maintenance period, and during acute rejection episodes to modulate the immune response.

The global rise in solid organ transplants-covering kidneys, livers, hearts, lungs, and pancreases-is driving demand for reliable and safe immunosuppressive regimens. With survival rates improving due to surgical advancements and post-transplant monitoring, the long-term management of immune response has become a key therapeutic priority. The complexity of immune signaling pathways involved in allograft rejection requires multi-drug approaches, often combining calcineurin inhibitors (e.g., tacrolimus), mTOR inhibitors (e.g., sirolimus), corticosteroids, and antiproliferative agents like mycophenolate mofetil. Continuous innovation in these classes is enabling better tolerance, fewer infections, and reduced chronic toxicity.

How Are New Therapeutic Targets and Formulations Improving Rejection Management and Patient Outcomes?

Recent advancements in immunology and molecular pharmacology are leading to the development of novel immunosuppressive agents with more selective mechanisms of action and improved side effect profiles. Co-stimulation blockers (e.g., belatacept) and monoclonal antibodies (e.g., basiliximab) are offering targeted inhibition of T-cell activation pathways without the nephrotoxicity associated with traditional calcineurin inhibitors. These agents are particularly useful in renal transplant recipients and patients with comorbidities.

Formulation improvements-such as extended-release tablets, enteric-coated capsules, and nano-carrier-based drug delivery-are enhancing medication adherence and pharmacokinetic stability. Therapeutic drug monitoring (TDM) is becoming more precise through point-of-care assays and pharmacogenomic profiling, allowing clinicians to individualize dosing and reduce rejection risk. Research is also underway to develop tolerance-inducing regimens that may one day eliminate the need for lifelong immunosuppression. These innovations are significantly reshaping the post-transplant medication landscape and improving both graft survival and patient quality of life.

Which Patient Populations and Regional Health Systems Are Driving Demand for Anti-Rejection Medications?

Kidney transplant recipients represent the largest segment of immunosuppressive therapy users, followed by liver and heart transplant patients. Pediatric and geriatric transplant populations require specialized dosing and monitoring strategies, due to differences in metabolism and immune system behavior. Patients undergoing re-transplantation or those with high panel reactive antibodies (PRA) often require more potent or multi-line regimens to prevent rejection and graft failure.

The U.S. leads global adoption due to its high transplant volume, advanced donor-matching systems, and inclusion of immunosuppressants in public and private insurance plans. Europe maintains a strong position through coordinated transplant networks and centralized post-transplant care. Asia-Pacific is witnessing rapid growth, particularly in India, China, and Japan, where organ transplant programs are scaling up and immunosuppressant affordability is improving. Emerging markets in Latin America and the Middle East are expanding access through public health financing and regional partnerships with global pharma companies.

What Is Fueling Long-Term Growth and Strategic Innovation in the Organ Transplant Rejection Medications Market?

The growth in the organ transplant rejection medications market is driven by the increasing success rate and accessibility of transplant procedures, longer post-transplant survival, and rising organ donation rates globally. Lifelong reliance on immunosuppressive medications, coupled with a growing transplant-eligible patient population, ensures recurring demand and market stability. Additionally, innovations in precision dosing, targeted therapies, and biosimilar development are broadening treatment options while improving cost-effectiveness.

Pharmaceutical companies are exploring next-generation biologics, T-regulatory cell therapy, and gene-editing strategies to induce immune tolerance and reduce long-term drug dependency. Strategic collaborations between transplant centers, biotech firms, and academic institutions are fostering accelerated clinical trials and real-world data generation. Regulatory support for fast-tracking therapies that reduce chronic rejection and improve long-term graft function is further encouraging innovation. As the global transplant ecosystem evolves toward personalized, sustainable, and high-outcome protocols, the market for rejection medications will continue to expand and diversify.

SCOPE OF STUDY:

The report analyzes the Organ Transplant Rejection Medications market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antibodies, Antimetabolites, Steroids, Other Drug Classes); Transplant Type (Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Other Transplant Types); Distribution Channel (Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie Inc.
• Accord Healthcare Ltd.
• Astellas Pharma Inc.
• Biocon Limited
• Bristol-Myers Squibb Company
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Genzyme Corporation
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd.
• Hansa Biopharma AB
• Hikma Pharmaceuticals plc
• Mylan Laboratories Inc.
• Novartis AG
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Veloxis Pharmaceuticals A/S
• Viatris Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Organ Transplant Rejection Medications - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Number of Organ Transplant Procedures Globally Propels Demand for Anti-Rejection Therapies
  • Expansion of Immunosuppressive Drug Combinations Strengthens Business Case for Personalized Regimens
  • Increased Focus on Long-Term Graft Survival Throws the Spotlight on Maintenance Immunotherapy
  • Development of Novel Calcineurin Inhibitors and Co-Stimulation Blockers Enhances Drug Innovation Pipeline
  • Integration of TDM and Pharmacogenomics in Dosing Optimization Supports Personalized Immunosuppression
  • Growth in Xenotransplantation and Regenerative Grafts Expands Scope of Rejection Management Protocols
  • Regulatory Approvals of Long-Acting Injectables Drive Adoption of Patient-Friendly Delivery Formats
  • Surge in Research on Immune Tolerance Induction Generates Opportunities for Rejection-Free Transplants
  • Rising Awareness of Post-Transplant Infection Risk Spurs Interest in Selective Immunomodulators
  • Availability of Biosimilars for Key Immunosuppressants Improves Cost Accessibility in Emerging Markets
  • Expansion of Telemedicine for Transplant Follow-Up Supports Adherence to Medication Schedules
  • Challenges in Nonadherence and Drug Toxicity Highlight the Need for Better Tolerability Profiles
  • Growth in Kidney, Liver, and Heart Transplants Sustains Demand Across Multi-Organ Therapeutic Classes
  • Increased Investment in Cellular and Biologic Rejection Modulators Fuels Pipeline Diversification
  • Clinical Guidelines Supporting Early Withdrawal Strategies Strengthen Interest in Minimally Immunosuppressive Regimens
  • Global Organ Shortages and Ethical Complexities Reinforce the Need for Maximized Graft Longevity
  • Integration of AI in Graft Monitoring and Early Rejection Prediction Enhances Intervention Timeliness
  • Collaborations Between Pharma Companies and Transplant Centers Accelerate Clinical Trials and Access
  • Regulatory Initiatives for Fast-Tracking Orphan Immunosuppressive Therapies Create Market Advantages
  • Real-World Evidence on Long-Term Outcomes Supports Decision-Making in Drug Selection and Switching
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Organ Transplant Rejection Medications Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Organ Transplant Rejection Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Organ Transplant Rejection Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antimetabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Antimetabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Steroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Steroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Steroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospitals Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Kidney Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Kidney Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Kidney Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Liver Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Liver Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Liver Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Heart Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Heart Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Heart Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Lung Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Lung Transplant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Lung Transplant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Transplant Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Transplant Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Transplant Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• JAPAN
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• CHINA
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 68: China Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• EUROPE
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Organ Transplant Rejection Medications by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Organ Transplant Rejection Medications by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• FRANCE
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 89: France Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• GERMANY
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 116: UK Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Organ Transplant Rejection Medications by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Organ Transplant Rejection Medications by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• INDIA
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 173: India Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Organ Transplant Rejection Medications by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Organ Transplant Rejection Medications by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Organ Transplant Rejection Medications by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Organ Transplant Rejection Medications by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030
• AFRICA
  • Organ Transplant Rejection Medications Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Organ Transplant Rejection Medications by Drug Class - Antibodies, Antimetabolites, Steroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Organ Transplant Rejection Medications by Drug Class - Percentage Breakdown of Value Sales for Antibodies, Antimetabolites, Steroids and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Organ Transplant Rejection Medications by Distribution Channel - Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Organ Transplant Rejection Medications by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Organ Transplant Rejection Medications by Transplant Type - Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Organ Transplant Rejection Medications by Transplant Type - Percentage Breakdown of Value Sales for Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant and Other Transplant Types for the Years 2015, 2025 & 2030

IV. COMPETITION